We are joined with a friend of the podcast, Pat Smith, former sell side analyst on Bay St.  

In this episode we cover a broad range of topics including how investors are switching from simply reading headlines to analyzing fundamentals and why cannabis continues to be a value play.  

We discuss how the broader markets are impacting our sector, as well touch on how crypto, gold, bond yields and the vaccine roll out could affect cannabis.

Note: there is an echo in the audio if you listen using headphones; it goes away if you listen through a speaker. Sorry about that, new audio set up this time!

In this episode we talk about watching your back! Cannabis investing is buyer beware and investors should always be thinking about mitigating their downside risk.

We discuss our personal viewpoints, investment philosophies and trading tactics for minimizing your downside risk in cannabis investing 

In this episode we share our thoughts on the market before answering listener questions

- Back to future: how our current pullback is eerily reminiscent of 2019

- Comparisons to crypto, psychedelics and other speculative asset classes

- Legalization let down: why investors shouldn't be discouraged

Listener Questions:

- What do we think about the MSOS ETF? 

- Show new investors be worried if cannabis is regulated similar to alcohol? (see link)

- How do we feel about certain speculative "penny stocks"?

- Questions about cannabis companies exporting to the EU

- Are the Big 5 MSOs the best investments in the sector?

- If we had to start over again, what would our portfolios look like?

Correction: We mentioned 300K patient count in Germany; 300K is the number of prescriptions written; patient count is estimated much lower at 60K

Buckle up boys and girls - in this epic episode we have the one and only CannaVestments (Nick Gastevich) joining us for a deep dive into the big 5 MSOs (now including Verano).

In this episode we discuss

- Overall thoughts on the market and having a long term focus

- Core markets for each of the big 5

- Financial performance for Q4 and 2020

- Where the majority of profits are being generated today

- What excites us for the future of each company

Thanks to Nick for another great and extensive review

Connect with Nick:

Twitter - https://twitter.com/CannaVestments

LinkedIn - https://www.linkedin.com/in/nicholas-gastevich-75841346/

Family Office Website - https://www.vginvests.com/ 

Story time! In this episode we get nostalgic and share our experiences of the ups and downs of cannabis investing from 2017-2019. 

In what was truly the boom and bust of speculative cannabis investing we learned some hard lessons which can be instructive for newer investors.

In this episode:

- Starting with a bang in 2017 with Canopy and Aphria

- Investing in a company at 30c and hitting a 20X return...then watching it come back

- How a private California deal went wrong

- Lessons learned through tough experiences 

In this episode we dive into the psychology behind the sharp pullback our sector has seen and we ask - what are cannabis investors so afraid of?

Agenda:

- Common Retail Mistakes that we see taking place

- The Momentum Trade dying down and what this means

- New York Legalizes! What this means for the industry 

- SAFE and Legalization Talks

- GTI and the Crisis of Confidence

- What we were scared of in the past (and what's changed)

- What are retail investors really afraid of?

Ascend Wellness S1: https://sec.report/Document/0001628280-21-005806/ 

Wall Street Journal Article on Retail Investors Retreating: https://www.wsj.com/articles/individual-investors-retreat-from-markets-after-show-stopping-start-to-2021-11617528781

We are joined by a special guest, Manuj Grover from Aim Gro Consulting.  Manuj has over 20 years of experience in finance and has helped many private Cannabis companies gain access to US and Canadian investors via Regulation A (Reg A) raises, the most recent being Gage Cannabis.

In this episode we cover Reg A raises, one of the many ways for retail investors to participate in pre IPO investments, and how it’s changing the investing landscape as we know it.

The following topics are covered in more detail:

Reg A vs. traditional private placements

Criteria for tier 1 and tier 2 raises

Why Reg A is gaining popularity

Risks and rewards associated with investing in private companies

Dangers associated with Reg A raises

Link: Click here for SEC Form 1 Filings

Companies mentioned: GTII, Gage Cannabis, Juva Life

In this episode we delve deep into the mind of mysterious "retail investor". Since cannabis is a retail dominated market it is important to understand how this impacts volatility and the opportunities it creates.

We cover 3 main topics:

1. Who is Retail? What constitutes Retail vs Institutional?

2. What are the most common mistakes retail investors make?

3. How can we avoid making these mistakes?

In this episode we delve into the importance of digging deep into potential cannabis investments

We discuss:

- Why its important to do due diligence (DD) before investing

- Setting clear goals of what you hope to achieve

- How DD should help your understanding of the business and the operators

- What to look for in potential deals

- Where to look (public and private)

- Resources provided by the company

- The importance of public filings

Following up on last week's volatility cannabis investors are left asking - what now? In this episode we share our core thesis of buying weakness in US cannabis names (selectively and at the right valuations). However, we debate both sides of buying now vs waiting for more pain.

In this market update:

- Where are we now?

- Why rising bond yields matter and what cannabis investors should know

- How stimulus affects the short term

- Catalyst: NY Legalization

- Catalyst: SAFE & Uplisting

- Catalyst: Federal legalization

- How each of these could play out and how they could fail

- Strategies for adding or waiting depending on your portfolio

- Earnings season inbound for US Cannabis